Lessons From In Re Rigel Pharmaceuticals

Law360, New York (September 19, 2012, 10:56 AM EDT) -- In In re Rigel Pharmaceuticals Inc. Securities Litigation (9th Cir. Sept. 6, 2012), the United States Court of Appeals for the Ninth Circuit affirmed the dismissal of a putative securities class action against Rigel Pharmaceuticals Inc., certain of Rigel’s directors and officers, and underwriters of Rigel’s February 2008 stock offering.

In a published opinion, the court held plaintiffs failed to sufficiently plead a false or misleading statement, and that the complaint’s allegations failed to meet the heightened requirements for pleading scienter under the Private Securities Litigation...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.